Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC
(MedPage Today) -- CHICAGO -- In patients with metastatic EGFR-positive lung cancer who progressed on targeted agents, adding pembrolizumab (Keytruda) to a standard chemotherapy regimen demonstrated no survival benefit, a randomized trial found...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Non-Small Cell Lung Cancer